)
Techno Medica (6678) investor relations material
Techno Medica Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
H1 FY2027 net sales rose 8.5% YoY to ¥4,453.6m; operating profit increased 75.7% to ¥468.2m and profit rose 58.2% to ¥321.3m.
Net assets were ¥13,224.0m at September 30, 2026, with an equity-to-asset ratio of 85.4%.
Financial highlights
Gross profit increased to ¥2,155.6m from ¥1,956.9m; SG&A edged down to ¥1,687.4m from ¥1,690.4m.
Ordinary profit rose 65.0% YoY to ¥485.7m; net profit was ¥321.3m versus ¥203.1m.
Basic EPS increased to ¥48.94 from ¥29.31.
Outlook and guidance
FY2027 annual dividend forecast revised to ¥97 per share, comprising ¥0 for the first half and ¥97 at fiscal year-end; FY2026 annual dividend was ¥129.
- Strong profit growth and higher EPS, but lower assets and reduced dividend forecast.6678
Q1 2027 - Q1 profits and revenue surged on robust sales, with full-year guidance maintained.6678
Q1 2025 - Revenue up, profits down; overseas sales strong, cost pressures persist, outlook unchanged.6678
Q2 2025 - Revenue steady, but profits fell sharply on higher costs; outlook unchanged.6678
Q3 2025 - Revenue fell 3.7% as domestic delays offset strong overseas growth; profits declined year-over-year.6678
Q4 2025 - Q1 FY2026 revenue fell 12.1% and net income dropped 90.5% year-over-year.6678
Q1 2026 - Slight revenue and profit declines, but guidance and dividend unchanged; strong equity ratio.6678
Q2 2026 - Revenue and profit surged on robust blood collection system sales; outlook remains strong.6678
Q3 2026 - Revenue and profit rose on robust blood collection system sales, but FY2027 outlook is cautious.6678
Q4 2026
Next Techno Medica earnings date
Next Techno Medica earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)